![](https://scx1.b-cdn.net/csz/news/tmb/2020/2-patient.jpg)
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by ...
May 28, 2020
0
8